PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications - PubMed (original) (raw)
doi: 10.1002/gcc.20939. Epub 2011 Nov 1.
Affiliations
- PMID: 22045666
- DOI: 10.1002/gcc.20939
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications
Maisa Yoshimoto et al. Genes Chromosomes Cancer. 2012 Feb.
Abstract
Deletion of PTEN at 10q23.3 occurs in ∼40% of human prostate cancers and is associated with aggressive metastatic potential, poor prognosis, and androgen-independence. This high frequency of recurrent PTEN deletions in prostate cancer suggests there may be unusual genomic features close to this locus that facilitate DNA alteration at 10q23.3. To explore possible mechanisms for deletions in the PTEN region, a meta-analysis of 311 published human genome array datasets was conducted and determined that the minimal prostate cancer-associated deletion at 10q23.3 corresponds to ∼2.06 MB region flanked by BMPR1A and FAS. On a separate cohort comprising an additional 330 tumors, four-color fluorescence in situ hybridization analysis using probes for BMPR1A, FAS, cen(10), and PTEN showed that 132 of 330 (40%) tumors had PTEN loss, 50 (15%) of which were homozygous losses (comprising in total 100 deletion events). Breakpoints between PTEN and BMPR1A or FAS were subsequently mapped in 100 homozygous and 82 hemizygous PTEN losses, revealing that 125/182 PTEN microdeletions occurred within the 940 kB interval between BMPR1A and PTEN. Furthermore, this breakpoint interval coincides with a repeat-rich region of 414 kB containing the SD17 and SD18 segmental duplications, which contain at least 13 homologous inverted repeat sequences. Together, these data suggest that a strong selective growth advantage for loss of PTEN and upregulation of PI3K/AKT, combined with the close proximity of PTEN to a large unstable segment of repeated DNA comprising SD17 and SD18, can lead to recurrent microdeletions of the PTEN gene in prostate cancer. © 2011 Wiley Periodicals, Inc.
Copyright © 2011 Wiley-Liss, Inc.
Similar articles
- Genomic Rearrangements of PTEN in Prostate Cancer.
Phin S, Moore MW, Cotter PD. Phin S, et al. Front Oncol. 2013 Sep 17;3:240. doi: 10.3389/fonc.2013.00240. Front Oncol. 2013. PMID: 24062990 Free PMC article. Review. - FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA. Yoshimoto M, et al. Br J Cancer. 2007 Sep 3;97(5):678-85. doi: 10.1038/sj.bjc.6603924. Epub 2007 Aug 14. Br J Cancer. 2007. PMID: 17700571 Free PMC article. - PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, Squire JA. Sircar K, et al. J Pathol. 2009 Aug;218(4):505-13. doi: 10.1002/path.2559. J Pathol. 2009. PMID: 19402094 - PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA. Bismar TA, et al. BJU Int. 2011 Feb;107(3):477-85. doi: 10.1111/j.1464-410X.2010.09470.x. BJU Int. 2011. PMID: 20590547 - Juvenile polyposis and other intestinal polyposis syndromes with microdeletions of chromosome 10q22-23.
Dahdaleh FS, Carr JC, Calva D, Howe JR. Dahdaleh FS, et al. Clin Genet. 2012 Feb;81(2):110-6. doi: 10.1111/j.1399-0004.2011.01763.x. Epub 2011 Sep 6. Clin Genet. 2012. PMID: 21834858 Free PMC article. Review.
Cited by
- Race and prostate cancer: genomic landscape.
Arenas-Gallo C, Owiredu J, Weinstein I, Lewicki P, Basourakos SP, Vince R Jr, Al Hussein Al Awamlh B, Schumacher FR, Spratt DE, Barbieri CE, Shoag JE. Arenas-Gallo C, et al. Nat Rev Urol. 2022 Sep;19(9):547-561. doi: 10.1038/s41585-022-00622-0. Epub 2022 Aug 9. Nat Rev Urol. 2022. PMID: 35945369 Review. - Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Sumanasuriya S, De Bono J. Sumanasuriya S, et al. Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):a030635. doi: 10.1101/cshperspect.a030635. Cold Spring Harb Perspect Med. 2018. PMID: 29101113 Free PMC article. Review. - The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.
Turnham DJ, Bullock N, Dass MS, Staffurth JN, Pearson HB. Turnham DJ, et al. Cells. 2020 Oct 22;9(11):2342. doi: 10.3390/cells9112342. Cells. 2020. PMID: 33105713 Free PMC article. Review. - Genomic Rearrangements of PTEN in Prostate Cancer.
Phin S, Moore MW, Cotter PD. Phin S, et al. Front Oncol. 2013 Sep 17;3:240. doi: 10.3389/fonc.2013.00240. Front Oncol. 2013. PMID: 24062990 Free PMC article. Review. - PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.
Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor H, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM. Lotan TL, et al. Mod Pathol. 2015 Jan;28(1):128-137. doi: 10.1038/modpathol.2014.85. Epub 2014 Jul 4. Mod Pathol. 2015. PMID: 24993522 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous